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Three months after a coronavirus disease (COVID-19) 
outbreak in Kupferzell, Germany, a population-based 
study (n = 2,203) found no RT-PCR-positives. IgG-ELISA 
seropositivity with positive virus neutralisation tests 
was 7.7% (95% confidence interval (CI): 6.5–9.1) and 
4.3% with negative neutralisation tests. We estimate 
12.0% (95% CI: 10.4–14.0%) infected adults (24.5% 
asymptomatic), six times more than notified. Full hot-
spot containment confirms the effectiveness of prompt 
protection measures. However, 88% naïve adults are 
still at high COVID-19 risk.
After a large church concert on 1 March 2020 and a 
first detected infection with severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) on 9 March, the 
southern German community of Kupferzell in the fed-
eral state Baden-Württemberg faced a steep increase 
of SARS-CoV-2 infections. Investigations of the local 
health authorities showed increasing evidence of com-
munity spreading in a complex and chronologically 
dense pattern of travel returnees who attended a choir 
and trombone church concert. Wide-reaching infection 
prevention and local control measures were imple-
mented starting in the week of the first case detec-
tion, followed by additional measures such as a ban on 
gatherings in the federal state starting mid-March. The 
number of SARS-CoV-2 infections peaked in March but 
waned in April, and there were only three cases in May 
(Figure). There were three deaths, aged 59, 81 and 91 
years. The cumulative incidence of 1,760 per 100,000 
in Kupferzell by the end of April was, at the time of the 
study, one of the highest in Germany. The Robert Koch 
Institute (RKI) set out to analyse the SARS-CoV-2 sero-
prevalence in a random sample of this community from 
20 May to 9 June.
CoMoLo study
The seroepidemiological study in Kupferzell, Germany 
is part of the population-based corona-monitoring 
local (CoMoLo) study that investigates the prevalence 
of SARS-CoV-2 IgG antibodies and of current infections 
in four communities with a high case incidence. Details 
are provided in the study protocol [1].
A random sample of 3,534 Kupferzell residents aged 18 
years and older from the mandatory population registry 
(68.9% of the 5,128 adult residents) was invited to take 
part in the study, and 2,203; (48.5% women; 18–94 
years;  Table 1) had venous blood sampling (Figure). 
These participants were 63% of those eligible. Some 
2,184 had SARS-CoV-2 RT-PCR testing of throat swabs 
targeting the E gene and the orf1ab region of SARS-
CoV-2 [2]. The Robert Koch Institute performed SARS-
CoV-2-S1 IgG-ELISA (Euroimmun, Lübeck, Germany) 
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Figure
Notified COVID-19 cases in adults 18 years and older and flow-chart of study design, Kupferzell, Germany, March–June 
2020 (n = 5,128)
Problems with the appointment/participation (n = 133); eligible but refusal (n = 133); eligible, miscellaneous 
reasons for non-participation (n = 46); no answer, unknown eligibility (n = 987); not eligible (n = 32)
n = 3,534 random population registry sample, age ≥ 18 years
n = 2,203 analysis sample with venous blood specimens
PCR (n = 2,184), all negative
IgG-ELISA (n = 2,203) negative
n = 2,203






































Characteristics of study population, COVID-19 cases 18 years and older, Kupferzell, Germany, 20 May–9 June 2020 
(n = 2,203)
n Weighted % 95% CI
Sex
Female 1,143 48.5 46.6–50.3
Male 1,060 51.5 49.7–53.4
Age female
18–34 years 379 25.1 22.8–27.7
35–49 years 279 23.6 21.2–26.3
50–64 years 282 28.5 25.8–31.4
≥ 65 203 22.7 20.1–25.5
Age male
18–34 years 334 26.6 23.8–29.6
35–49 years 254 26.2 23.3–29.3
50–64 years 290 28.2 25.6–31.1
≥ 65 182 18.9 16.5–21.6
Secondary school education
Lower 670 42.8 40.3–45.3
Middle 731 28.2 26.4–30.1
Higher 744 29.0 26.9–31.1
Household size
1 person 227 11.4 10.0–13.0
2 persons 729 34.3 31.7–36.9
3–4 persons 877 39.0 36.3–41.8
> 4 persons 324 15.3 13.2–17.8
Exposures
Working with patients 204 10.0 8.6–11.5
Working with customers 432 21.3 19.3–23.3
Travelled abroad since 1 January 361 15.0 13.4–16.9
Participated in event with ≥ 50 persons 636 26.4 24.3–28.6
Quarantine or isolation
Voluntary 256 11.8 10.3–13.4
Mandated 317 14.3 12.6–16.2
Self-reported health
Very good 739 31.6 29.5–33.7
Good 1,156 55.2 52.9–57.4
Moderate/bad/very bad 247 13.2 11.7–14.9
Medical conditions
Self-reported COVID-19 50 2.4 1.8–3.2
Chronic conditionsa 638 35.3 33.0–37.7
Symptoms since 1 February
Fever ≥ 38 °C 209 9.6 8.3–11.1
Dyspnoea, shortness of breath 145 6.6 5.6–7.9
Pneumonia 11 0.5 0.3–1.0
Congested/running nose 627 28.6 26.5–30.8
Cough 549 25.0 23.0–27.1
Pain when breathing 76 3.5 2.7–4.4
Sore throat 558 24.0 22.1–26.0
Loss of smell or taste 131 6.0 5.0–7.2
No symptoms 1,042 51.2 48.8–53.7
Mild symptoms only 922 41.8 39.4–44.2
Moderate or severe symptoms (pneumonia, dyspnoea) 153 7.0 5.9–8.3
CI: confidence interval; COVID-19: coronavirus disease.
a Lung or heart disease, diabetes, stroke, hypertension, immunodeficiency.
Complementary categories are not always shown, e.g. ‘not working with patients’ and missing values are not shown, therefore n do not 
always add up to the total.
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and applied the thresholds provided in the manual [1]. 
All samples that tested SARS-CoV-2-S1-IgG-positive 
(ratio ≥ 1.1) or indeterminate (ratio ≥ 0.8 to < 1.1) were 
additionally tested for neutralising antibodies with 
plaque reduction neutralisation tests (prNT) [3] at the 
German consultant laboratory for human coronaviruses 
at Charité – Universitätsmedizin Berlin.
Underascertainment of SARS-CoV-2 infections was 
calculated as the ratio of two population proportions: 
the proportion of SARS-CoV-2 infections calculated 
from our study and the cumulative incidence of non-
fatal PCR-positive cases in the adult population of 
Kupferzell calculated from notified cases aged 18 years 
and older. Proportions of IgG-positives were adjusted 
for sensitivity (88.3%) and specificity (99.2%) of the 
Euroimmun S1-SARS-CoV-2 IgG test [4], according to 
validity studies conducted by the Paul Ehrlich Institute. 
These validity studies had tested 513 pre-pandemic 
specimens and 222 convalescent coronavirus disease 
(COVID-19) patients, the vast majority (96%) at least 21 
days after symptom onset (personal communication, 
H. Scheiblauer, 30 Sep 2020).
Statistical analyses were conducted using SAS 9.4 sur-
vey procedures. Results were weighted to the popula-
tion of Kupferzell with regard to age group, sex and 
school education (district level). Clustering within 
households was taken into account.
Ethical statement
This study was approved by the ethics committee of the 
Berlin Chamber of Physicians (Berliner Ärztekammer, 
reference number Eth-11/20), and the data commis-
sioner of the Robert Koch Institute. All participants 
gave informed consent.
Seroprevalence
All SARS-CoV-2 swabs taken during the study were neg-
ative in RT-PCR. The population-weighted prevalence 
of indeterminate IgG results was 1.9%; positive IgG 
results occurred with a prevalence of 11.3% or, when 
corrected for test performance, 12.0% (95% confidence 
interval (CI): 10.4–14.0) (Table 2). The lowest IgG sero-
prevalence in women was among the 18–34 year-olds, 
in men among the 35–49 year-olds. Factors associ-
ated with seropositivity were loss of smell or taste, 
fever ≥ 38 °C, a history of travelling or attending a large 
event and very good self-reported health. The associa-
tion of seropositivity with ‘quarantine or isolation’ is 
not surprising since these participants were likely to 
be either diagnosed COVID-19 cases or close contacts. 
None of the participants with indeterminate IgG had a 
positive prNT, i.e. neutralising antibodies. The popula-
tion-weighted seroprevalence of anti-SARS-CoV-2 IgG 
with positive prNT was 7.7% (95% CI: 6.5–9.1). 
Cumulative incidence of SARS-CoV-2 
infections
For the cumulative incidence of SARS-CoV-2 infections, 
we considered current infections (in this study none 
because all study PCR tests were negative) and past 
infections. The vast majority of past infections can 
be identified by IgG antibodies, but not all [5]: in the 
subgroup of 50 participants with self-reported COVID-
19 diagnosis done before the study period, only 89% 
(weighted percentage; 95% CI: 77.3–95.0) were IgG-
positive (Table 3). The seropositivity rate in the 26 par-
ticipants with self-reported COVID-19 diagnosis with 
mild symptoms was 87% (weighted percentage; 95% 
CI: 70.7–95.1) and in those with moderate-to-severe 
symptoms (n = 16) it was 94% (weighted percentage; 
95% CI: 66.5–99.3). However, this was well taken into 
account by the mathematical correction for sensitivity 
and specificity since the corrected proportion of sero-
positives among these 50 participants was ca 100%. 
24.5% of seropositive participants reported that they 
had not had any of the eight investigated symptoms 
since 1 February (16.8% of those with neutralising 
antibodies).
The underascertainment ratio comparing IgG seroposi-
tivity corrected for test performance, with the officially 
reported cumulative incidence was 6.1 (95% CI: 5.2–
7.0). If calculated based on seropositivity of both IgG 
and prNT, the underascertainment ratio would be 3.9 
(95% CI: 3.2–4.6).
Discussion
Seroepidemiological studies are key to understanding 
the distribution of infections in the population, despite 
uncertainties deriving from test performance and from 
the proportion of infected persons who never develop 
or have declining levels of antibodies [5-10].
Our results of 12% IgG-seropositive participants cor-
rected for test performance and a proportion of 25% 
asymptomatic infections are in line with the results 
from the German high-prevalence towns Gangelt [10] 
and Neustadt am Rennsteig [11]. Seroepidemiological 
studies conducted in Germany [12] are systematically 
tracked by the German national public health institute 
(Robert Koch Insitute;  www.rki.de/covid-19-serostud-
ies-germany). The cumulative incidence of infections 
of 15.5% in Gangelt [13] was based on RT-PCR-positive 
cases and on positive or indeterminate S1-ELISA-
Euroimmun IgG tests, corrected for the manufacturer-
provided sensitivity of 90.9% and specificity of 99.1%. 
From Neustadt am Rennsteig [11], a seroprevalence of 
8.4% was reported, based on two of six different IgG 
immunoassays. Testing of a pre-existing population-
based cohort in the low-prevalence area of Bonn yielded 
a seroprevalence of ca 1%, based on positive S1-ELISA-
Euroimmun IgG tests and 0.36% with both S1-ELISA-IgG 
and neutralising antibodies [14]. Compared with other 
European areas with high COVID-19 prevalence such as 
Ischgl in Austria [15] or the Lodi Red Zone in Lombardy, 
Italy, [16] the seroprevalence in Kupferzell was still low.
The increased odds of infection after travelling abroad 
and after participating in larger events are in line with 
the outbreak history in Kupferzell. From our study and 
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Table 2a
Prevalence of SARS-CoV-2 IgG and neutralising antibodies in adults and association with sociodemographic, exposure and 
clinical characteristics, Kupferzell, Germany, 20 May–9 June 2020 (n = 2,203)
Prevalence of positive 
results in both IgG-ELISA 








prevalence of IgG 
ratio ≥ 1.1 
 
corrected for sensitivity 
88.3% and specificity 
99.2%
OR for being 
IgG-seropositive 





(IgG-ELISA; n = 249)





% 95% CI OR 95% CI
Weighted 
% 95% CI
Total 167 7.7 6.5–9.1 249 11.3 12.0 10.4–14.0 Nd Nd
Female 96 8.7 7.1–10.7 136 12.2 13.0 10.8–15.6 1 Reference 52.1 46.1–58.1
Male 71 6.7 5.2–8.5 113 10.5 11.1 9.0–13.6 0.86 0.67–1.12 47.9 41.9–53.9
Age female
18–34 years 23 5.4 3.5–8.1 31 7.5 7.7 5.1–11.3 1 Reference 15.5 10.8–21.7
35–49 years 20 7.2 4.6–11.1 39 14.3 15.4 11.0–21.0 2.04 1.21–3.44 27.6 20.6–36.0
50–64 years 30 10.3 7.3–14.4 39 13.4 14.4 10.4–19.5 1.90 1.16–3.12 31.3 23.8–39.9
≥ 65 23 12.0 8.1–17.5 27 13.7 14.8 10.0–21.2 1.95 1.12–3.42 25.5 18.2–34.5
Age male
18–34 years 25 7.2 4.7–10.8 40 11.3 12.0 8.2–17.1 1 Reference 28.6 20.7–38.1
35–49 years 6 2.4 1.0–5.3 11 4.5 4.3 1.9–8.4 0.37 0.18–0.78 11.2 6.2–19.6
50–64 years 23 8.1 5.4–12.0 37 12.9 13.9 9.9–19.0 1.16 0.70–1.93 34.7 26.2–44.3
≥ 65 17 9.8 6.1–15.3 25 14.2 15.3 10.2–22.3 1.30 0.73–2.32 25.5 17.6–35.4
Secondary school education
Lower 61 9.0 6.7–11.8 82 11.6 12.3 9.7–15.5 0.92 0.62–1.35 43.3 36.5–50.3
Middle 58 8.4 6.2–11.2 86 12.2 13.0 10.3–16.3 1.10 0.78–1.55 30.0 24.5–36.1
Higher 46 6.0 4.2–8.6 78 10.6 11.2 8.6–14.4 1 Reference 26.8 21.5–32.8
Household size
1 person 14 6.8 4.0–11.3 21 9.6 10.1 6.2–15.7 0.79 0.46–1.37 9.6 6.2–14.5
2 persons 57 8.0 6.0–10.6 82 11.5 12.2 9.5–15.5 1 Reference 34.5 27.9–41.8
3–4 persons 71 8.3 6.4–10.7 106 12.1 12.9 10.2–16.2 1.29 0.90–1.84 41.5 34.4–48.9
> 4 persons 23 6.2 3.7–10.2 37 10.7 11.4 7.1–17.4 1.13 0.67–1.90 14.4 9.5–21.2
Exposures
Working with 
patients 23 12.0 8.0–17.6 30 14.9 16.1 10.9–23.0 1.41 0.90–2.22 13.3 9.3–18.8
Working with 
customers 31 7.7 5.2–11.1 48 11.9 12.7 9.2–17.2 1.16 0.79–1.71 22.7 17.1–29.5
Travelled abroad 
since 1 January 31 8.9 5.8–13.5 58 16.7 18.1 13.3–24.2 1.93 1.31–2.83 21.9 16.4–28.7
Event with ≥ 50 
persons 68 11.9 9.3–15.2 102 17.2 18.8 15.0–23.1 2.24 1.63–3.07 39.8 33.2–46.7
Quarantine or isolation
Voluntary 28 11.8 8.1–16.9 40 17.3 18.9 13.7–25.5 3.34 2.17–5.15 18.4 13.5–24.5
Mandated 80 25.4 20.5–31.1 104 33.1 36.9 30.4–44.1 8.68 6.00–12.55 42.5 35.4–50.0
CI: confidence interval; COVID-19: coronavirus disease; ELISA: enzyme-linked immunosorbent assay; Nd: not done; OR: odds ratio; prNT: 
plaque reduction neutralisation tests; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
a Not corrected for sensitivity and specificity.
b Lung or heart disease, diabetes, stroke, hypertension, immunodeficiency.
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the three other German studies with available data, 
the underascertainment ratio has been smaller than 6 
[11,13,14] and not 10 or higher as in a number of inter-
national locations [17]. The association of seropositiv-
ity with very good self-reported health, although not 
statistically significant, may be indicative of lower 
risk awareness and less protective behaviour. As the 
CoMoLo study continues in three other locations, 
more detailed analyses might be possible with a larger 
sample.
According to a recent report of IgG levels stable for 
up to 4 months on the one hand [18], and reports on 
waning of neutralising antibodies on the other hand 
[10,19,20], we base our estimate of the cumulative inci-
dence of infections on IgG antibodies. However, in our 
subsample of 50 participants with self-reported PCR-
based COVID-19 diagnoses, 11% were not IgG-positive 
which is in line with large population-based studies 
from Spain and New York State [21,22]. The cumula-
tive incidence of infection in this subgroup, which was 
based on IgG corrected for sensitivity and specificity, 
Prevalence of positive 
results in both IgG-ELISA 








prevalence of IgG 
ratio ≥ 1.1 
 
corrected for sensitivity 
88.3% and specificity 
99.2%
OR for being 
IgG-seropositive 





(IgG-ELISA; n = 249)









Very good 57 7.7 5.9–10.0 95 13.1 14.0 11.2–17.5 1.41 1.04–1.90 36.0 30.0–42.4
Good 92 8.1 6.5–10.1 127 11.1 11.8 9.6–14.3 1 Reference 53.2 46.8–59.6
Moderate/bad/
very bad 15 6.3 3.8–10.2 23 9.4 9.8 6.2–14.9 0.69 0.42–1.14 10.8 7.2–15.8
Medical conditions
Self-reported 
COVID-19 34 71.6 57.8–82.3 43 89.0 100.8 88.0–107.5 81.20
34.78–
189.55 19.2 14.2–25.4
Chronic conditionsb 53 8.9 6.7–11.7 71 11.6 12.3 9.5–15.8 0.78 0.55–1.10 35.4 28.9–42.4
Symptoms since 1 February





28 19.4 13.4–27.3 36 25.8 28.5 20.6–38.2 2.80 1.81–4.33 14.6 10.5–20.1
Pneumonia Nd 4 Nd Nd Nd Nd
Congested/running 
nose 74 11.6 9.0–14.8 102 16.0 17.3 13.9–21.4 1.88 1.39–2.56 39.0 32.7–45.7
Cough 76 14.1 11.1–17.7 101 18.6 20.4 16.5–25.0 2.34 1.73–3.17 39.9 33.5–46.7
Pain when 
breathing 13 17.0 10.0–27.5 17 22.9 25.3 15.4–38.6 2.39 1.31–4.36 6.8 4.2–10.9
Sore throat 55 10.1 7.6–13.1 68 12.5 13.3 10.2–17.2 1.20 0.86–1.68 25.7 20.3–31.9
Loss of smell or 
taste 69 54.9 45.8–63.7 92 71.5 80.8 70.8–89.3 30.49
19.68–
47.25 36.5 30.2–43.3
No symptoms 24 2.6 1.7–4.0 55 5.6 5.5 3.9–7.6 1 Reference 24.5 18.9–31.1
Mild symptoms 





29 19.2 13.3–26.8 39 26.8 29.7 21.8–39.2 6.30 3.85–10.30 16.1 11.7–21.7
CI: confidence interval; COVID-19: coronavirus disease; ELISA: enzyme-linked immunosorbent assay; Nd: not done; OR: odds ratio; prNT: 
plaque reduction neutralisation tests; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
a Not corrected for sensitivity and specificity.
b Lung or heart disease, diabetes, stroke, hypertension, immunodeficiency.
Complementary categories are not always shown, e.g. ‘not working with patients’ and missing values not shown, therefore n do not always 
add up to the total.
Table 2b
Prevalence of SARS-CoV-2 IgG and neutralising antibodies in adults and association with sociodemographic, exposure and 
clinical characteristics, Kupferzell, Germany, 20 May–9 June 2020 (n = 2,203)
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took these seronegative infected persons almost per-
fectly into account. However, with increasing time lag 
between pandemic wave and serosurveys, some addi-
tional adjustment for seroreversion may be necessary 
when estimating the cumulative incidence. Of note, 
validation studies for serological assays should have 
sufficient sample sizes in the healthy group, where 
specificity is calculated, and in the infected group, 
where sensitivity is calculated. In addition, they should 
aim for representativeness of the target population 
as well as clinical outcome (mild and severe COVID-
19) and address cross-reactivity concerns by includ-
ing subgroups of patients with other respiratory virus 
infections including seasonal cororavirus [23].
In Neustadt am Rennsteig, only 20 of 38 (53%; 95% CI: 
37–69) previously PCR-positive persons were seroposi-
tive, which may be due to a different testing strategy 
(whole community screening) that tested more asymp-
tomatic cases and to the definition of seropositivity 
(at least two of six different antibody tests needed to 
be positive). Therefore, seronegative infected persons 
may not have been taken into account sufficiently and 
the underlying cumulative incidence of infections may 
have been as high as 8.4 per 0.52, i.e. 16%. We there-
fore propose that estimates of the cumulative incidence 
of infections should be based not only on antibody 
testing but also on current and past PCR test results. 
Within each study, the subsample of previously PCR-
positive participants, i.e. participants for whom sero-
logical and virological results are available, provides 
valuable information for estimating the cumulative inci-
dence of infections. It can be used to evaluate whether 
correction for diagnostic sensitivity, e.g. mathematical 
correction or combination of different immunoassays, 
is appropriate for the specific study.
Conclusion
This study confirmed that even in areas with high 
COVID-19 prevalence, only a small proportion of the 
population has been infected. Therefore, ongoing pro-
tective measures are justified. Moreover, this is the 
second German study on a community outbreak that 
shows that these measures are highly effective, lead-
ing at least temporarily to full containment [11].
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Table 3
Participants with self-reported COVID-19 diagnosis, Kupferzell, Germany, 20 May–9 June 2020 (n = 50)
Total 18–49 years ≥ 50 years
Total (n unweighted) 50 25 25
Mean age in years (range) 52 (19–81) 37 (19–49) 63 (50–81)
n Column % a 95% CI n
Column 
% a 95% CI n
Column 
% a 95% CI
IgG-positive 43 89.0 77.3–95.0 19 79.1 58.6–91.0 24 95.9 74.6–99.5
IgG-positive, corrected for sensitivity 
88.3% and specificity 99.2% 43 100.8 87.4–107.7 19 89.5 66.0–103.1 24 108.7 84.3–112.8
IgG-positive and prNT-positive 34 71.6 57.3–82.6 13 54.6 34.3–73.5 21 83.5 62.5–93.9
Chronic conditionsb 19 45.8 31.5–60.9 6 29.5 13.2–53.6 13 57.7 36.5–76.5
No symptoms 2 Nd 2 Nd 0 Nd
Mild symptoms only 31 61.4 45.9–74.9 18 70.6 47.7–86.3 13 55.0 34.9–73.6
Moderate-to-severe symptoms 
(pneumonia, dyspnoea/shortness of 
breath)
17 34.4 21.6–49.9 5 19.2 7.7–40.6 12 45.0 26.4–65.1
CI: confidence interval; COVID-19: coronavirus disease; Nd: not done; OR: odds ratio; prNT: plaque reduction neutralisation tests; SARS-
CoV-2: severe acute respiratory syndrome coronavirus 2.
a Weighted %.
b Lung or heart disease, diabetes, stroke, hypertension, immunodeficiency.
There were no indeterminate IgG results. Of note, while n are unweighted, proportions are weighted and can therefore not be calculated from 
the numbers in this table.
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